House E&C chair racks up campaign contributions from more than 30 biopharma companies so far in 2023

Rep. Cathy Mc­Mor­ris Rodgers (R-WA) chairs the most im­por­tant House com­mit­tee, En­er­gy and Com­merce, when it comes to bio­phar­ma in­ter­ests. And her 2024 re­elec­tion cam­paign has al­ready reaped more than $100,000 in con­tri­bu­tions in 2023 from more than 30 bio­phar­ma com­pa­nies, ac­cord­ing to fil­ings with the Fed­er­al Elec­tion Com­mis­sion.

Ef­fec­tive­ly serv­ing as the last line of de­fense for Re­pub­li­cans (with De­moc­rats con­trol­ling the Sen­ate and pres­i­den­cy) on all things phar­ma-re­lat­ed, Mc­Mor­ris Rodgers is ready­ing new leg­is­la­tion this fall around PBM re­forms, pan­dem­ic pre­pared­ness, and key drug short­ages that have caused de­layed or no ac­cess to com­mon can­cer treat­ments.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters